Download PDF
Hamostaseologie 1996; 16(01): 6-14
DOI: 10.1055/s-0038-1656632
Übersichtsarbeiten/Review Articles
Schattauer GmbH

Non-anticoagulant functions of heparin and heparan sulfate

E. Buddecke
1   Institute for Physiological Chemistry and Pathobiochemistry (Director: Prof. Dr. P. Bruckner), University of Münster
› Author Affiliations
Further Information

Publication History

Publication Date:
26 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

Heparin is known to bind a large number of proteins not involved in anticoagula-tion, such as growth factors, adhesive proteins of the extracellular matrix, viral coat proteins and other enzymes and proteins. In vivo predominantly heparan sulfate – the most ubiquitous cell surface glycosaminoglycan – takes the functional role of heparin. Structural features, sources and non-anticoagulant func-tions of heparin and heparan sulfate proteoglycan are described. The functional diversity of heparin and heparan sulfate is reviewed in the following sections: (I) heparin and heparan sulfate as partners in fibroblast growth factor action, (II) antiproliferative effects of heparan sulfate and heparin, (III) cell surface heparan sulfate as extracellular matrix receptor and coreceptor, (IV) proteoheparan sulfate in central and peripheral nervous system, (V) role of proteoheparan sulfate in binding and uptake of lipoproteins, (VI) virus and spirochete binding to heparin and heparan sulfate.

Keywords

Proteoheparan sulfate - heparin - inhibition of proliferation - growth factor binding - extracellular matrix receptors
 

  • REFERENCES

  • 1 Jorpes E. The chemistry of heparin. Bio-chem J 1935; 29: 1817-24
    CrossrefPubMedGoogle Scholar
  • 2 Hirsch H. Heparin. N Engl J Med 1991; 324: 1565-72
    CrossrefPubMedGoogle Scholar
  • 3 Lee MK, Lander AD. Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: development of a sensitive electrophoretic approach. Proc Natl Acad Sci 1991; 88: 2768-72
    CrossrefPubMedGoogle Scholar
  • 4 Lindahl U, Kusche M, Lidholt K, Oscarsson LG. Biosynthesis of heparin and heparan sulfate. Ann New York Acad Sci 1989; 556: 36-50
    CrossrefPubMedGoogle Scholar
  • 5 Schmidt A, Lemming G, Yoshida K, Buddecke E. Molecular organization and antiproliferative domains of arterial tissues heparan sulfat. Eur J Cell Biol 1992; 59: 322-8
    PubMedGoogle Scholar
  • 6 Schmidt A, Yoshida K, Buddecke E. The antiproliferative activity of arterial heparan sulfate resides in domains enriched with 2-O-sulfated uronic acid residues. J Biol Chem 1992; 267: 19242-7
    PubMedGoogle Scholar
  • 7 Carey DJ, Stahl RC. Identification of a lipid-anchored heparan sulfate proteoglycan in Schwann cells. J Cell Biol 1990; 111: 2053-62
    CrossrefPubMedGoogle Scholar
  • 8 Clement B, Segui-Real B, Hassel JR. et al. Identification of acell surface-binding protein for the core protein of the basement membrane proteoglycan. J Biol Chem 1989; 264: 12467-71
    PubMedGoogle Scholar
  • 9 Bernfield M, Kokenyesi R, Kato M. et al. Biology of the syndecans: A family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992; 8: 365-93
    CrossrefPubMedGoogle Scholar
  • 10 Kjellén L, Lindahl U. Proteoglycans; Structures and interactions. Annu Rev Biochem 1991; 60: 443-75
    CrossrefPubMedGoogle Scholar
  • 11 Zhou F, Höök T, Thompson JA, Höök M. Heparin protein interactions. In: Heparin and Related Polysaccharides. Lane DA, Björk I, Lindahl U. (eds). New York: Plenum Press; 1992: 141-53
    Google Scholar
  • 12 Aviezer D, Levy E, Safran M. et al. Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J Biol Chem 1994; 269: 114-21
    PubMedGoogle Scholar
  • 13 Burgess WH, Maciag T. The heparin-bind-ing fibroblast growth factor family of proteins. Annu Rev Biochem; 1989; 58: 575-606
    CrossrefPubMedGoogle Scholar
  • 14 Shworak NW, Kojima T, Rosenberg RD. Isolation and characterization of ryudocan and syndecan heparan sulfate proteoglycans core proteins and cDNAs from a rat endothelial cell line Haemostasis. 1993; 23: 161-76
    PubMedGoogle Scholar
  • 15 Pierce A, Lyon M, Hampson IN. et al. Molecular cloning of the major cell surface heparan sulfate proteoglycan from rat liver. J Biol Chem 1992; 267: 3894-900
    PubMedGoogle Scholar
  • 16 Carey DC, Evans DM, Stahl RAC. et al. Molecular cloning and characterization of N-syndecan, a novel transmembrane heparan sulfate proteoglycan. J Cell Biol 1992; 117: 191-201
    CrossrefPubMedGoogle Scholar
  • 17 Baciu PC, Howard WB, Goetinck PF. Prediction of a novel integral membrane proteoglycan core protein related to syndecan and fibroglycan. J Cell Biol 1991; 115: 125a
    PubMedGoogle Scholar
  • 18 Andres JL, Rönnstrand L, Cheifetz S, Massagué J. Purification of the transforming growth factor-ß (TGF-ß) binding proteoglycan betaglycan. J Biol Chem 1991; 266: 23282-7
    PubMedGoogle Scholar
  • 19 Fransson LA, Carlstedt I, Cöster L, Malmström A. Binding of transferin to the core protein of fibroblast proteoheparan sulfate. Proc Natl Acad Sci. USA 1984; 81: 5657-61
    PubMedGoogle Scholar
  • 20 Brown TA, Bouchard TSt., John T. et al. Human keratinocytes express a new CD44 core protein (CD44E) as a heparan sulfate intrinsic membrane proteoglycan with additional exons. J Cell Biol 1991; 113: 207-21
    CrossrefPubMedGoogle Scholar
  • 21 Lories V, Cassiman JJ, Van den Berghe H, David G. Differential expression of cell surface heparan sulfate proteoglycans in human mammary epithelial cells and lung fibroblasts. J Biol Chem 1992; 267: 1116-22
    PubMedGoogle Scholar
  • 22 Schmidt A, Buddecke E. Bovine arterial smooth muscle cells synthesize two functionally different proteoheparan sulfate species. 1990; 189: 269-75
    PubMedGoogle Scholar
  • 23 Murdoch AD, Dodge GR, Cohen I. et al. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). J Biol Chem 1992; 267: 8544-57
    PubMedGoogle Scholar
  • 24 Maccarana M, Casu B, Lindahl U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem 1993; 268: 23898-905
    PubMedGoogle Scholar
  • 25 Tyrrell DJ, Ishihara M, Rao N. et al. Structure and biological activities of a heparin-derived hexasaccharide with high affinity for basic fibroblast growth factor. J Biol Chem 1993; 268: 4684-89
    PubMedGoogle Scholar
  • 26 Turnbull JE, Fernig DG, Ke Y. et al. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 1992; 267: 10337-41
    PubMedGoogle Scholar
  • 27 Gallagher JT, Turnbull JE. Heparan sulphate in the binding and activation of basic fibroblast growth factor. Glycobiology 1992; 2: 523-8
    CrossrefPubMedGoogle Scholar
  • 28 Walker A, Turnbull JE, Gallagher JT. Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. J Biol Chem 1994; 269: 931-5
    PubMedGoogle Scholar
  • 29 Springer BA, Pantoliano MW, Barbera FA. et al. Identification and concerted function of two receptor binding surfaces on basic fibroblast growth factor required for mito-genesis. J Biol Chem 1994; 269: 26879-84
    PubMedGoogle Scholar
  • 30 Schmidt A, Buddecke E. Cell-associated proteoheparan sulfate from bovine arterial smooth muscle cells. Exp Cell Res 1988; 178: 242-53
    CrossrefPubMedGoogle Scholar
  • 31 Fritze LMS, Reilly CF, Rosenberg RD. An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol 1985; 100: 1041-9
    CrossrefPubMedGoogle Scholar
  • 32 Clowes AW, Karnovsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977; 265: 625-6
    CrossrefPubMedGoogle Scholar
  • 33 More RS, Brack MJ, Gerschlick AH. Heparin after angioplasty: an unresolved issue. Eur Heart J 1993; 14: 1543-7
    CrossrefPubMedGoogle Scholar
  • 34 Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation 1992; 84: 1426-36
    PubMedGoogle Scholar
  • 35 Fedarko NS, Conrad HE. A unique heparan sulfate in the nuclei of hepatocytes: structural changes with the growth state of the cells. J Cell Biol 1986; 102: 587-99
    CrossrefPubMedGoogle Scholar
  • 36 Karnovsky MJ, Wright jr TC , Castellot jr JJ. et al. Heparin heparan sulfate, smooth muscle cells and atherosclerosis. Ann N Y Acad Sci 1989; 556: 268-81
    CrossrefPubMedGoogle Scholar
  • 37 Guimond S, Maccarana M, Olwin BB. et al. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). J Biol Chem 1993; 268: 23906-14
    PubMedGoogle Scholar
  • 38 McCaffrey TA, Falcone DJ, Brayton CF. et al. Transforming growth factor-ß activity is potentiated by heparin via dissociating of the transforming growth factor-ß/2-macroglobu-lin inactive complex. J Cell Biol 1989; 109: 441-8
    CrossrefPubMedGoogle Scholar
  • 39 Goodman LV, Majack RA. Vascular smooth muscle cells express distinct transforming growth factor-ß receptor phenotypes as a function of cell density in culture. J Biol Chem 1989; 264: 5241-4
    PubMedGoogle Scholar
  • 40 Grainger DJ, Witchell CM, Watson JV. et al. Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor beta-like activity from serum. Cardiovasc Res 1993; 27: 2238-47
    PubMedGoogle Scholar
  • 41 Pukac LA, Ottlinger ME, Karnovsky MJ. Heparin suppresses specific second messenger pathways for protooncogene expression in rat vascular smooth muscle cells. J Biol Chem 1992; 267: 3707-11
    PubMedGoogle Scholar
  • 42 Bennett MR, Littlewood TD, Hancock DC. et al. Down-regulation of the c-myc protooncogene in inhibition of vascular smooth muscle cell proliferation: a signal for growth arrest?. Biochem J 1994; 302: 701-8
    CrossrefPubMedGoogle Scholar
  • 43 Hamno M, Bauters C, Wernert N. et al. Heparin does not inhibit oncogene induction in rabbit aorta following balloon denudation. Cardiovasc Res 1993; 27: 1209-13
    CrossrefPubMedGoogle Scholar
  • 44 Skaletz-Rorowski A, Schmidt A, Breithardt G, Buddecke E. Heparin-induced overex-pression of basic fibroblast growth factor, basic fibroblast growth factor receptor and cell-associated proteoheparan sulfate in cultured coronary smooth muscle cells. Arte-rioscl Thromb Vasc Biol (in press)
    PubMedGoogle Scholar
  • 45 Koda JE, Bernfield M. Heparan sulfate proteoglycans from mouse mammary epithelial cells: basal extracellular proteoglycans bind specifically to native type I collagen fibrils. J Biol Chem 1984; 259: 11763-70
    PubMedGoogle Scholar
  • 46 Saunders S, Bernfield M. Cell surface proteoglycan binds mouse mammary eptithelial cells to fibronectin and behaves as a receptor for interstitial matrix. J Cell Biol 1988; 106: 423-30
    CrossrefPubMedGoogle Scholar
  • 47 Yoneda J, Saiki I, Igarashi Y. et al. Role of the heparin-binding domain of chimeric peptides derived from fibronectin in cell spreading and motility. Exp Cell Res 1995; 217: 169-79
    CrossrefPubMedGoogle Scholar
  • 48 Weber P, Zimmermann DR, Winterhalter KH, Vaughan L. Tenascin-C binds heparin by its fibronectin type III domain five. J Biol Chem 1995; 270: 4619-23
    CrossrefPubMedGoogle Scholar
  • 49 Ramasamy S, Lipke DW, McClain CJ, Hennig B. Tumor necrosis factor reduces proteoglycan synthesis in cultured endothelial cells. J Cell Physiol 1995; 162: 119-26
    CrossrefPubMedGoogle Scholar
  • 50 Salmivirta M, Mali M, Heino J. et al. A novel laminin binding form of syndecan-1 (cell surface proteoglycan) produced by syndecan-1 cDNA-transfected NIH-3T3 cells. Exp Cell Res 1994; 215: 180-8
    CrossrefPubMedGoogle Scholar
  • 51 Mayer U, Zimmermann K, Mann K. et al. Binding properties and protease stability of recombinant human nidogen. Eur J Biochem 1995; 227: 681-6
    CrossrefPubMedGoogle Scholar
  • 52 Sun X, Mosher DF, Rapraeger A. Heparan sulfate-mediated binding of epithelial cell surface proteoglycan to thrombospondin. J Biol Chem 1989; 264: 2885-9
    PubMedGoogle Scholar
  • 53 Marinides GN, Suchard SJ, Mookerjee BK. Role of thrombospondin in mesangial cell growth: possible existence of an autocrine feedback growth circuit. Kidney Int 1994; 46: 350-7
    CrossrefPubMedGoogle Scholar
  • 54 Karthikeyan L, Flad M, Engel M. et al. Im-munocytochemical and in situ hybridization studies in the heparan sulfate proteoglycan, glypican, in nervous tissue. J Cell Sci 1994; 107: 3213-22
    PubMedGoogle Scholar
  • 55 Tsen G, Halfter W, Kroger S, Cole GJ. Agrin is a heparan sulfate proteoglycan. J Biol Chem 1995; 270: 3392-9
    CrossrefPubMedGoogle Scholar
  • 56 Small DH, Reed G, Whitefield B, Nurcombe V. Cholinergic regulation of neurite outgrowth from isolated chick sympatheti neurons in culture. J Neurosci 1995; 15: 144-51
    CrossrefPubMedGoogle Scholar
  • 57 Lafont F, Prochiantz A, Valenza C. et al. Defined glycosaminoglycan motifs have opposite effects on neuronal polarit in vitro. Dev Biol 1994; 165: 453-68
    CrossrefPubMedGoogle Scholar
  • 58 Sekiguchi RT, Potter-Perigo S, Braun K. et al. Characterization of proteoglycans synthesized by murine embryonal carcinom cells (P19) reveals increased expression of per-lecan (heparan sulfate proteoglycan) during neuronal differentiation. J Neurosci Res 1994; 38: 670-86
    CrossrefPubMedGoogle Scholar
  • 59 Peng HB, Ali AA, Dai Z. et al. The role of heparin binding growth associated molecule (HB-GAM) in the postsynaptic induction in cultured muscle cells. J Neurosci 1995; 15: 3027-38
    CrossrefPubMedGoogle Scholar
  • 60 Beisiegel U, Weber W, Bengtsson-Olive-crona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 1991; 88: 8342-6
    CrossrefPubMedGoogle Scholar
  • 61 Roskams T, Moshage H, De-Vos R. et al. Heparan sulfate pro-teoglycan expression in normal human liver. Hepatology 1995; 21: 950-8
    CrossrefPubMedGoogle Scholar
  • 62 Ji ZS, Brecht WJ, Miranda RD. et al. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem 1993; 268: 10160-7
    PubMedGoogle Scholar
  • 63 Nykjaer A, Nielsen M, Lookene A. et al. A carboxyl-terminal fragment of lipoprotein lipase binds to the low density lipoprotein receptor related protein and inhibits lipase-mediated uptake of lipoprotein in cells. J Biol Chem 1994; 269: 31747-55
    PubMedGoogle Scholar
  • 64 Ji ZS, Mahley RW. Lactoferrin binding to heparan sulfate proteoglycans and the LDL receptor-related protein. Further evidence supporting the importance of direct binding of remnant lipoproteins to HSPG. Arterio-scler Thromb 1994; 14: 2025-31
    CrossrefPubMedGoogle Scholar
  • 65 Mulder M, Lombardi P, Jansen H. et al. Heparan sulphate proteoglycans are involved in the lipoprotein lipase-mediated enhancement of the cellular binding of very low density and low density lipoproteins. Biochem Biophys Res Commun 1992; 185: 582-7
    CrossrefPubMedGoogle Scholar
  • 66 Williams KJ, Fless GM, Petrie KA. et al. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein (a), low density lipoprotein, and nascent lipoproteins. J Biol Chem 1992; 267: 13284-92
    PubMedGoogle Scholar
  • 67 Roderiquez G, Oravecz T, Yanagishita M. et al. Mediation of human immunodeficiency virus type 1 binding to interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gpl20-gp41. J Virol 1995; 69: 2233-9
    PubMedGoogle Scholar
  • 68 Newburg DS, Linhardt RJ, Ampofo SA, Yolken RH. Human milk glycosaminogly-cans inhibit HIV glycoprotein gpl20 binding to its host cell CD4 receptor. J Nutr 1995; 125: 419-24
    PubMedGoogle Scholar
  • 69 Shiek MT, WuDunn D, Montgomary RI. et al. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol 1992; 116: 1273-81
    CrossrefPubMedGoogle Scholar
  • 70 Leong JM, Morrissey PE, Ortega-Barria E. et al. Hemagglutination and proteoglycan binding of the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 1995; 63: 874-83
    PubMedGoogle Scholar
  • 71 Brown KJ, Parish CR. Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor. Biochemistry 1994; 33: 13918-27
    CrossrefPubMedGoogle Scholar
  • 72 Spring J, Goldberger OA, Jenkins NA. et al. Mapping of the syndecan genes in the mouse: linkage with members of the myc gene family. Genomics 1994; 21: 597-601
    CrossrefPubMedGoogle Scholar
  • 73 Schriever C, Schmidt A, Breithardt G, Buddecke E. Human recombinant insulin-like growth factor I and II stimulate the expression of basic fibroblast growth factor but supprsses the division of bovine coronary smooth muscle cells. Atherosclerosis (in press) .
    PubMedGoogle Scholar
  • 74 Kovalszky H, Gallai M, Armbrust T, Rama-dori G. Syndecan-1 gene expression in isolated rat liver cells (hepatocytes, Kupffer cells, endothelial and Ito cells). Biochem Biophys Res Commun 1994; 204: 944-9
    CrossrefPubMedGoogle Scholar
  • 75 Kim CW, Goldberger OA, Gallo RL, Bern-field M. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol Biol Cell 1994; 5: 797-805
    CrossrefPubMedGoogle Scholar
  • 76 Wang ZH, Manabe T, Ohshio G. et al. Im-munohistochemical study of heparan sulfate proteoglycan in adenocarcinomas of the pancreas. Pancreas 1994; 9: 758-63
    CrossrefPubMedGoogle Scholar
  • 77 Schmidt A, Skaletz-Rorowski A, Breithardt G, Buddecke E. Growth status-dependent changes of bFGF compartmentalization and heparan sulfate structure in arterial smooth muscle cells. Eur J Cell Biol 1995; 67: 130-5
    PubMedGoogle Scholar